{"aid": "40260251", "title": "Personalized mRNA vaccine boosts melanoma immunotherapy", "url": "https://www.nature.com/articles/d41591-024-00006-4", "domain": "nature.com", "votes": 18, "user": "blegr", "posted_at": "2024-05-04 21:01:58", "comments": 0, "source_title": "Personalized mRNA vaccine boosts melanoma immunotherapy", "source_text": "Personalized mRNA vaccine boosts melanoma immunotherapy\n\nSkip to main content\n\nThank you for visiting nature.com. You are using a browser version with\nlimited support for CSS. To obtain the best experience, we recommend you use a\nmore up to date browser (or turn off compatibility mode in Internet Explorer).\nIn the meantime, to ensure continued support, we are displaying the site\nwithout styles and JavaScript.\n\nAdvertisement\n\n  * View all journals\n  * Search\n\n## Search\n\nAdvanced search\n\n### Quick links\n\n    * Explore articles by subject\n    * Find a job\n    * Guide to authors\n    * Editorial policies\n\n  * Log in\n\n  * Explore content\n  * About the journal\n  * Publish with us\n  * Subscribe\n\n  * Sign up for alerts\n  * RSS feed\n\n  * RESEARCH HIGHLIGHT\n  * 25 January 2024\n\n# Personalized mRNA vaccine boosts melanoma immunotherapy\n\nIn patients with resected, high-risk melanoma, the addition of a personalized\nmRNA-based neoantigen therapy to adjuvant pembrolizumab was more effective\nthan pembrolizumab alone.\n\nBy\n\n  * Karen O\u2019Leary^0\n\n  1. Karen O\u2019Leary\n\n    1. Karen O\u2019Leary is an Associate Research Analysis Editor with Nature Medicine.\n\nView author publications\n\nYou can also search for this author in PubMed Google Scholar\n\n  * Twitter\n  * Facebook\n  * Email\n\nAdjuvant checkpoint inhibitor therapy is the standard of care for resectable\nmelanoma. Although many patients derive lasting benefit from the treatment, a\nsubstantial number experience disease recurrence.\n\n## Access options\n\nAccess through your institution\n\nChange institution\n\nBuy or subscribe\n\nAccess Nature and 54 other Nature Portfolio journals\n\nGet Nature+, our best-value online-access subscription\n\n24,99 \u20ac / 30 days\n\ncancel any time\n\nLearn more\n\nSubscribe to this journal\n\nReceive 12 print issues and online access\n\n209,00 \u20ac per year\n\nonly 17,42 \u20ac per issue\n\nLearn more\n\nRent or buy this article\n\nPrices vary by article type\n\nfrom$1.95\n\nto$39.95\n\nLearn more\n\nPrices may be subject to local taxes which are calculated during checkout\n\ndoi: https://doi.org/10.1038/d41591-024-00006-4\n\n## Related Articles\n\n  * Precision medicine meets cancer vaccines\n\n  * CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial\n\n  * Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial\n\n  * Read more research highlights selected by the Nature Medicine team\n\n## Subjects\n\n  * RNA vaccines\n  * Clinical trials\n  * Cancer therapy\n\n## Latest on:\n\nNeutralization, effector function and immune imprinting of Omicron variants\n\nArticle 30 AUG 23\n\nAlgorithm for optimized mRNA design improves stability and immunogenicity\n\nArticle 02 MAY 23\n\nSARS-CoV-2 Omicron boosting induces de novo B cell response in humans\n\nArticle 03 APR 23\n\nClinical trial links oncolytic immunoactivation to survival in glioblastoma\n\nArticle 18 OCT 23\n\nA COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity\n\nArticle 23 NOV 21\n\nTwo chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity\n\nArticle 30 JUN 21\n\nDiscovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers\n\nArticle 24 APR 24\n\nPGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial\nfunction\n\nArticle 24 APR 24\n\nFOXO1 is a master regulator of memory programming in CAR T cells\n\nArticle 10 APR 24\n\nNeutralization, effector function and immune imprinting of Omicron variants\n\nArticle 30 AUG 23\n\nAlgorithm for optimized mRNA design improves stability and immunogenicity\n\nArticle 02 MAY 23\n\nSARS-CoV-2 Omicron boosting induces de novo B cell response in humans\n\nArticle 03 APR 23\n\n### Jobs\n\n  * #### Seeking Global Talents, the International School of Medicine, Zhejiang University\n\nWelcome to apply for all levels of professors based at the International\nSchool of Medicine, Zhejiang University.\n\nYiwu, Zhejiang, China\n\nInternational School of Medicine, Zhejiang University\n\n  * #### Assistant, Associate, or Full Professor\n\nAthens, Georgia\n\nUniversity of Georgia\n\n  * #### Associate Professor - Synthetic Biology\n\nPosition Summary We seek an Associate Professor in the department of Synthetic\nBiology (jcvi.org/research/synthetic-biology). We invite applicatio...\n\nRockville, Maryland\n\nJ. Craig Venter Institute\n\n  * #### Associate or Senior Editor (microbial genetics, evolution, and epidemiology) Nature Communications\n\nJob Title: Associate or Senior Editor (microbial genetics, evolution, and\nepidemiology), Nature Communications Locations: London, New York, Philade...\n\nNew York (US)\n\nSpringer Nature Ltd\n\n  * #### Postdoctoral Research Fellow\n\nTwo postdoctoral positions offered at HMS to study the role hypothalamic\nleptin resistance in control of neuron activity\n\nBoston, Massachusetts (US)\n\nBoston Children\u2019s Hospital-Ozcan Lab\n\nAccess through your institution\n\nChange institution\n\nBuy or subscribe\n\n## Related Articles\n\n  * Precision medicine meets cancer vaccines\n\n  * CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial\n\n  * Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial\n\n  * Read more research highlights selected by the Nature Medicine team\n\n## Subjects\n\n  * RNA vaccines\n  * Clinical trials\n  * Cancer therapy\n\n## Sign up to Nature Briefing\n\nAn essential round-up of science news, opinion and analysis, delivered to your\ninbox every weekday.\n\nSign up for the Nature Briefing newsletter \u2014 what matters in science, free to\nyour inbox daily.\n\nGet the most important science stories of the day, free in your inbox. Sign up\nfor Nature Briefing\n\nNature Medicine (Nat Med) ISSN 1546-170X (online) ISSN 1078-8956 (print)\n\n## nature.com sitemap\n\n### About Nature Portfolio\n\n  * About us\n  * Press releases\n  * Press office\n  * Contact us\n\n### Discover content\n\n  * Journals A-Z\n  * Articles by subject\n  * protocols.io\n  * Nature Index\n\n### Publishing policies\n\n  * Nature portfolio policies\n  * Open access\n\n### Author & Researcher services\n\n  * Reprints & permissions\n  * Research data\n  * Language editing\n  * Scientific editing\n  * Nature Masterclasses\n  * Research Solutions\n\n### Libraries & institutions\n\n  * Librarian service & tools\n  * Librarian portal\n  * Open research\n  * Recommend to library\n\n### Advertising & partnerships\n\n  * Advertising\n  * Partnerships & Services\n  * Media kits\n  * Branded content\n\n### Professional development\n\n  * Nature Careers\n  * Nature Conferences\n\n### Regional websites\n\n  * Nature Africa\n  * Nature China\n  * Nature India\n  * Nature Italy\n  * Nature Japan\n  * Nature Middle East\n\n  * Privacy Policy\n  * Use of cookies\n  * Legal notice\n  * Accessibility statement\n  * Terms & Conditions\n  * Your US state privacy rights\n  * Cancel contracts here\n\n\u00a9 2024 Springer Nature Limited\n\n", "frontpage": true}
